Profile data is unavailable for this security.
About the company
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.
- Revenue in USD (TTM)0.00
- Net income in USD-9.74m
- Incorporated2015
- Employees10.00
- LocationBluejay Diagnostics Inc360 Massachusetts Avenue, Suite 203ACTON 01720United StatesUSA
- Phone+1 (978) 631-0152
- Fax+1 (302) 636-5454
- Websitehttps://bluejaydx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PainReform Ltd | 0.00 | -12.54m | 1.29m | 6.00 | -- | 0.5206 | -- | -- | -7.77 | -7.77 | 0.00 | 0.9988 | 0.00 | -- | -- | 0.00 | -158.88 | -55.47 | -222.89 | -68.20 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -6.28 | -- | -- | -- |
| LadRx Corp | 0.00 | 1.66m | 1.37m | 2.00 | 0.8014 | 3.96 | 0.8170 | -- | 3.44 | 3.44 | 0.00 | 0.6973 | 0.00 | -- | -- | 0.00 | 96.28 | -58.97 | -- | -78.44 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 106.96 | -- | -- | -- |
| Lucy Scientific Discovery Inc | 16.73k | -9.76m | 1.37m | -- | -- | 16.85 | -- | 81.76 | -6.34 | -7.21 | 0.0103 | 0.046 | 0.0037 | -- | 0.7276 | -- | -215.45 | -- | -- | -- | 49.97 | -- | -58,360.55 | -- | -- | -5.10 | 0.4615 | -- | -- | -- | -53.49 | -- | -- | -- |
| Agentix Corp | 0.00 | -1.01m | 1.42m | -- | -- | -- | -- | -- | -0.0253 | -0.0253 | 0.00 | -0.071 | 0.00 | -- | -- | -- | -907.08 | -- | -- | -- | -- | -- | -- | -- | -- | -96.41 | -- | -- | -- | -- | -- | -- | -- | -- |
| Nexien Biopharma Inc | 0.00 | -246.18k | 1.43m | 0.00 | -- | -- | -- | -- | -0.0038 | -0.0038 | 0.00 | -0.0048 | 0.00 | -- | -- | -- | -679.40 | -860.53 | -- | -1,653.53 | -- | -- | -- | -- | -- | -1.77 | -- | -- | -- | -- | 42.22 | -- | -- | -- |
| Dermata Therapeutics Inc | 0.00 | -8.69m | 1.44m | 8.00 | -- | 4.46 | -- | -- | -24.67 | -24.67 | 0.00 | 0.5717 | 0.00 | -- | -- | 0.00 | -120.05 | -- | -146.08 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.90 | -- | -- | -- |
| 180 Life Sciences Corp | 0.00 | -16.24m | 1.46m | 4.00 | -- | -- | -- | -- | -41.54 | -41.54 | 0.00 | -1.12 | 0.00 | -- | -- | 0.00 | -176.90 | -42.39 | -354.57 | -56.41 | -- | -- | -- | -- | -- | -385.88 | -- | -- | -- | -- | 48.52 | -- | -- | -- |
| Target Group Inc | 5.64m | 228.87k | 1.48m | 46.00 | 18.46 | -- | 1.39 | 0.2626 | 0.0001 | 0.0001 | 0.0088 | -0.0115 | 0.764 | 8.60 | 124.27 | 115,104.10 | 3.10 | -37.99 | -- | -78.76 | 43.71 | -- | 4.06 | -586.97 | 0.0736 | 0.0149 | 3.10 | -- | -- | 577.83 | 92.84 | -- | -58.54 | -- |
| Bluejay Diagnostics Inc | 0.00 | -9.74m | 1.48m | 10.00 | -- | 0.4072 | -- | -- | -7.68 | -7.68 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -122.06 | -- | -149.68 | -- | -- | -- | -- | -- | -- | -- | 0.0048 | -- | -100.00 | -- | -7.07 | -- | -- | -- |
| Panacea Life Sciences Holdings Inc | 2.76m | -7.67m | 1.57m | 40.00 | -- | -- | -- | 0.5688 | -0.4554 | -0.4554 | 0.164 | -0.5255 | 0.1537 | 1.62 | 10.13 | 69,098.25 | -42.65 | -69.04 | -- | -225.03 | -139.49 | -181.62 | -277.51 | -505.41 | 0.0285 | -2.12 | 4.79 | -- | 46.59 | -- | 12.33 | -- | -- | -- |
| Mallinckrodt PLC | 1.91bn | -1.49bn | 1.60m | 2.80k | -- | -- | -- | 0.0008 | -161.65 | -161.63 | 89.63 | 55.44 | 0.4062 | 1.57 | 4.94 | 681,821.40 | -31.61 | -12.49 | -36.10 | -15.85 | 26.22 | 35.68 | -77.83 | -44.38 | 1.63 | -0.3456 | 0.6164 | -- | -2.53 | -10.31 | -83.00 | -- | -- | -- |
| Mustang Bio Inc | 0.00 | -40.10m | 1.63m | 80.00 | -- | -- | -- | -- | -4.55 | -4.55 | 0.00 | -0.4757 | 0.00 | -- | -- | 0.00 | -90.93 | -70.02 | -138.05 | -79.98 | -- | -- | -- | -- | -- | -15.88 | -- | -- | -- | -- | 33.44 | -- | -60.75 | -- |
| Stemcell Holdings Inc | 9.98m | 3.10m | 1.64m | -- | -- | -- | 0.5008 | 0.1645 | 0.00008 | 0.00008 | 0.0003 | 0.0002 | 1.12 | -- | 5.20 | -- | 34.90 | -- | 68.19 | -- | 77.19 | -- | 31.04 | -- | -- | -- | 0.00 | -- | 85.10 | -- | 71.82 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Sabby Management LLCas of 31 Mar 2024 | 187.29k | 6.45% |
| Armistice Capital LLCas of 31 Mar 2024 | 176.00k | 6.06% |
| Citadel Securities LLCas of 31 Mar 2024 | 19.85k | 0.68% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 17.10k | 0.59% |
| Virtu Americas LLCas of 31 Mar 2024 | 10.64k | 0.37% |
| XTX Markets LLCas of 31 Mar 2024 | 10.53k | 0.36% |
| Tower Research Capital LLCas of 31 Mar 2024 | 7.18k | 0.25% |
| Osaic Wealth, Inc. (Investment Management)as of 31 Mar 2024 | 25.00 | 0.00% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 10.00 | 0.00% |
| JPMorgan Asset Management (Europe) SARL (Germany)as of 31 Mar 2024 | 0.00 | 0.00% |
